Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients - Wikidata - wikimedia - TriplyDB

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients

http://www.wikidata.org/entity/Q28290930

about

Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability Immunopathology of synovitis: from histology to molecular pathways Gene expression analysis in RA: towards personalized medicine Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system.Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial.Sterol intermediates of cholesterol biosynthesis inhibit hair growth and trigger an innate immune response in cicatricial alopecia.Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis.Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis.Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study.Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients.Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab.Gene Expression Profiling in Peripheral Blood Cells and Synovial Membranes of Patients with Psoriatic Arthritis A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm.The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases.Rituximab Downregulates Gene Expression Associated with Cell Proliferation, Survival, and Proteolysis in the Peripheral Blood from Rheumatoid Arthritis Patients: A Link between High Baseline Autophagy-Related ULK1 Expression and Improved Pain Contro Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study Immune cell profiling to guide therapeutic decisions in rheumatic diseases The type I interferon signature in leukocyte subsets from peripheral blood of patients with early arthritis: a major contribution by granulocytes Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study Cytokines as biomarkers in rheumatoid arthritis.The potential use of expression profiling: implications for predicting treatment response in rheumatoid arthritis.Cognitive consequences of a sustained monocyte type 1 IFN response in HIV-1 infection Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine.Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.Transcriptional Repression of IFN Regulatory Factor 7 by MYC Is Critical for Type I IFN Production in Human Plasmacytoid Dendritic Cells Emerging aspects of molecular biomarkers for diagnosis, prognosis and treatment response in rheumatoid arthritis.Omics studies: their use in diagnosis and reclassification of SLE and other systemic autoimmune diseases.Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics.Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis.The RNA-binding protein HuR/ELAVL1 regulates IFN-β mRNA abundance and the type I IFN response.Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis Gene Expression Analysis before and after Treatment with Adalimumab in Patients with Ankylosing Spondylitis Identifies Molecular Pathways Associated with Response to Therapy.Epstein-Barr virus infection transforms CD25+ B cells into antibody-secreting cells in rheumatoid arthritis patients.The interferon signature and STAT1 expression in rheumatoid arthritis synovial fluid macrophages are induced by tumor necrosis factor α and counter-regulated by the synovial fluid microenvironment.Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis.IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients.The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy.Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy.

P2860

Q26771652-27D25B62-2900-43F5-9D3C-8DBD0C020E5D Q26781647-AF448C28-5E29-42B4-8922-D40F9B02BA0C Q26825706-B969446C-0CE0-49FA-9606-A8C2DB9CF4B9 Q27692640-35E68120-2E6D-4DA6-9DBD-859F1547C396 Q30807010-14BE82F6-FAAA-4DB7-A760-A10C8C4F900B Q34299630-1345318F-423F-4980-9854-E0B28E78471D Q34535634-39139699-A204-4678-9B93-73110A7AC464 Q34810094-CF832860-40B8-4B82-91FE-3E1C5D1DEA1E Q35147055-E9CBEBD2-3612-4675-B8E6-41DFCA0485C0 Q35438412-6BCDF9AF-C188-423F-9AA7-DCBA1911E33C Q35559143-136FEBB3-B51D-454A-89CB-AEAB351456E3 Q35667354-8EEC0A71-A4FC-4A2C-AE18-47A1E0469E45 Q35835741-5EF7AC7E-B9ED-484F-AE40-B910D3A7E016 Q36245889-ACE7448C-8E9F-456B-85A9-35E508E6F4CF Q36338717-5F2E3D25-F5A7-4BDE-95DE-FD30976C008B Q36556219-CFDDF083-52E0-4225-A650-1382C13A0427 Q36825365-080D2757-3B7F-43CE-B313-F87C759AECBE Q36982828-AEDD88A5-3307-47D8-9B2D-63DB3A891154 Q37093897-612E7102-AB23-4405-9746-4136AD60E42F Q37111423-3B29B5EE-BE3E-4B65-B3A9-64D0696B07AC Q37661549-C1E8005E-E77B-4839-8E03-89CB662145CE Q38088942-CD66B0E9-1879-4127-A9D1-E5AA5B302DEB Q38214994-8F486268-9CFA-49EE-A296-5C3F6385794B Q38335622-ED74CE7C-D9CC-4F0A-BAF6-CFE1746BE338 Q38679589-27462E52-29A1-4149-97C9-AD9223C3FDA7 Q38746231-8F1836FD-DD33-4E24-849A-B6EC1778C408 Q38797638-059F9DA3-684D-4593-8173-800C1DB41E8C Q38879076-63265719-5F48-4938-8733-F7B7BCE43D18 Q38988559-60B8EA9D-A738-4DF8-A69A-49C22943D311 Q39367839-B6554DDD-DFCF-4A91-AD98-7E7250D991BF Q41441442-117D9203-5B1D-4AE7-90B4-622DAD2A9960 Q41632669-A593242C-F6C4-4BFC-84A8-41A927FDC8DB Q42081086-9BAADFEF-B500-433C-8DFA-7844414AAD7D Q42284576-E88C8B60-6971-4B2F-90F5-2958A362F9C5 Q42326768-7182CBEA-D242-4EE7-BADB-229C3A323954 Q42633541-CB01A07E-870A-4D08-8D30-168F9A7DECF9 Q42701821-849AA466-5918-4D09-8EDC-C2049D11BBDE Q43693855-584290D4-4E79-4B0E-9A0E-86D5F6D14006 Q47427257-5DAA1255-9010-4817-924F-971C05210EE4 Q51168774-CF9CB935-0E29-4EE7-8FFB-B7EF82BBA0ED

P2860

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients

http://www.wikidata.org/entity/Q28290930

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Relationship between the type ...... rheumatoid arthritis patients

@ast

Relationship between the type ...... rheumatoid arthritis patients

@en

Relationship between the type ...... rheumatoid arthritis patients

@nl

type

label

Relationship between the type ...... rheumatoid arthritis patients

@ast

Relationship between the type ...... rheumatoid arthritis patients

@en

Relationship between the type ...... rheumatoid arthritis patients

@nl

prefLabel

Relationship between the type ...... rheumatoid arthritis patients

@ast

Relationship between the type ...... rheumatoid arthritis patients

@en

Relationship between the type ...... rheumatoid arthritis patients

@nl

P1433

Q28290930-0816014D-F5BC-4BF7-9346-E1154770C128

P1476

Q28290930-703AA212-C406-41A3-95DE-B58A38459E7D

P2093

Q28290930-047100C2-2255-470A-BCA9-47719C4E5B01

Q28290930-15DD01A6-9BE8-4D0D-A07F-CAEADEC8C689

Q28290930-229613A6-9534-46CF-AF6F-917E4CA92DC7

Q28290930-61E8E370-C7B4-4F85-8273-6E52A83F70A4

Q28290930-620D4008-F1F8-45C8-9781-27E827EAB3D8

Q28290930-8415B46C-13F8-48A1-B014-09AD05BF6467

Q28290930-9FADB719-B47F-4B73-A1F8-7B8E9DEEAA15

Q28290930-A1E2746C-5BB6-4EB7-880D-ACF225FC81C2

Q28290930-B40BC9D1-CB5D-44DA-B201-B695AC7B834F

Q28290930-D00DB329-09AD-4B16-B6D8-93E7D4A15459

P2860

Q28290930-0158528C-EAFA-4F0C-AA11-9A23BFED4DC4

Q28290930-05403EB5-32C6-438F-9154-062F2AF1F238

Q28290930-103A1AA4-DC96-4B15-AFF3-5C039C472854

Q28290930-15B3A35E-DBB5-42EE-89C0-B99D7C4722B7

Q28290930-18757513-4BC7-4AE6-AF33-D09F3D2D8D7E

Q28290930-1D393B52-DF19-4257-914D-4C0570DBA3A6

Q28290930-1FCBBDB3-E950-4283-A102-1CEBB9985F2D

Q28290930-23CD8BF1-2C13-42EB-AEB6-008F4E9EC89A

Q28290930-278039E7-B31C-434E-BFDD-84DBE0965EAE

Q28290930-36F4016A-E16E-471B-91EE-E7C32EE84551

P304

Q28290930-225A7A98-395E-4B80-B3CF-61A307C85440

P31

Q28290930-34EF53A1-56F9-491C-86A3-EA5DF4A1EE2C

P3181

Q28290930-C0CC04CB-E6FC-4FCE-8C90-83F0BD7891AA

P356

Q28290930-ACB03AB2-3207-4773-9293-81CDFC6ABC8D

P407

Q28290930-9ECF1586-4188-4D42-AB3C-797DC6980138

P433

Q28290930-32552CBD-CBE3-42DD-83BE-D0F1BF35744B

P478

Q28290930-81FDA933-C5F6-4655-85F9-83D515304629

P50

Q28290930-003D2AC7-7951-4BD8-8373-A59D478FEB06

P577

Q28290930-2829B27E-6DEC-45F7-A06C-EB43384BFA9A

P5875

Q28290930-0E8416D1-0629-474D-9998-71BF87134BA1

P698

Q28290930-017ADD40-2A73-4F10-B2BC-83ADFBCB4F86

P921

Q28290930-5803419C-2CEF-4DFD-857A-19DA9849C863

P3181

P356

P1433

Arthritis and Rheumatism

P1476

Relationship between the type ...... rheumatoid arthritis patients

@en

P2093

Carina Bos

http://www.w3.org/2001/XMLSchema#string

Cornelis L Verweij

http://www.w3.org/2001/XMLSchema#string

Daisy Marie van Westing

http://www.w3.org/2001/XMLSchema#string

Danielle M Gerlag

http://www.w3.org/2001/XMLSchema#string

Janneke Tekstra

http://www.w3.org/2001/XMLSchema#string

Joel A van Roon

http://www.w3.org/2001/XMLSchema#string

Johannes W Bijlsma

http://www.w3.org/2001/XMLSchema#string

Koen Vos

http://www.w3.org/2001/XMLSchema#string

Kyriakos A Kirou

http://www.w3.org/2001/XMLSchema#string

Marie Boumans

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort

Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci

High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus

B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data.

Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Peripheral blood gene expression profiling in Sjögren's syndrome

IFN-beta in rheumatoid arthritis.

Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.

P304

3607-3614

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

39313

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/ART.27702

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

Lisa G van Baarsen

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45709980

http://www.w3.org/2001/XMLSchema#string

P698

20722020

http://www.w3.org/2001/XMLSchema#string

P921